MMWR Morb Mortal Wkly Rep. 2013 Apr 26;62(16):312.
Tubersol, a product of Sanofi Pasteur Limited, is in short supply nationwide until at least the end of May 2013. Tubersol is one of two purified-protein derivative (PPD) tuberculin products licensed by the Food and Drug Administration (FDA). The manufacturer has notified CDC that 50-dose vials of Tubersol will remain unavailable until the end of May 2013 and that supplies of 10-dose vials are still being reestablished: the product is available only by contacting Sanofi directly (at https://www.vaccineshoppe.com/index.cfm? or telephone, 800-822-2463). JHP Pharmaceuticals, LLC, the manufacturer of Aplisol, the other PPD tuberculin product licensed by FDA, has notified FDA that the product is available in restricted quantity. Acute local shortages of Aplisol also have been reported to CDC by TB control officials, as health-care providers switch from Tubersol to Aplisol. The shortages of Aplisol probably will diminish as Tubersol supplies are restored to their preshortage availability in the normal distribution networks. This report advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt to the shortage.
Tubersol，由赛诺菲巴斯德有限公司生产，在全国范围内的供应短缺至少持续到 2013 年 5 月底。Tubersol 是美国食品和药物管理局（FDA）批准的两种纯化蛋白衍生物（PPD）结核菌素产品之一。制造商已通知疾病预防控制中心，50 剂量瓶的 Tubersol 将在 2013 年 5 月底之前无法供应，而 10 剂量瓶的供应仍在重新建立中：只能通过直接联系赛诺菲（在 https://www.vaccineshoppe.com/index.cfm？或电话，800-822-2463）获得该产品。Aplisol 的制造商 JHP 制药有限责任公司已通知 FDA，该产品的供应数量有限。由于医疗保健提供者从 Tubersol 转向 Aplisol，结核病控制官员也向疾病预防控制中心报告了 Aplisol 的急性局部短缺情况。随着 Tubersol 供应恢复到正常分销网络的短缺前水平，Aplisol 的短缺情况可能会减少。本报告就如何应对短缺问题向公共卫生官员、临床医生以及职业健康和感染控制工作者提供建议。
